Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO…

Overview of attention for article published in BMC Cancer, June 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 64 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,219 followers.

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). https://t.co/qdkZJgneGM

13 Jan 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.